Industry
Biotechnology
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Loading...
Open
55.62
Mkt cap
2.2B
Volume
231K
High
58.98
P/E Ratio
-31.46
52-wk high
58.98
Low
55.62
Div yield
N/A
52-wk low
21.38
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 12:42 pm
Portfolio Pulse from Benzinga Newsdesk
October 08, 2024 | 4:40 pm
Portfolio Pulse from Avi Kapoor
October 08, 2024 | 2:12 pm
Portfolio Pulse from Benzinga Newsdesk
October 08, 2024 | 12:43 pm
Portfolio Pulse from Benzinga Newsdesk
October 01, 2024 | 5:14 pm
Portfolio Pulse from Benzinga Newsdesk
September 20, 2024 | 4:28 pm
Portfolio Pulse from Benzinga Newsdesk
September 03, 2024 | 11:49 am
Portfolio Pulse from Avi Kapoor
August 27, 2024 | 2:38 pm
Portfolio Pulse from Benzinga Newsdesk
August 27, 2024 | 12:12 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 12:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.